Strategic Acquisition IBAMNA was acquired by CapVest in 2016 and operates under the IHS umbrella, indicating solid backing and potential for expanded budgets and long-term collaborations in radiopharmaceutical manufacturing and distribution.

Radiopharma Growth As a leading developer, manufacturer and distributor of radiopharmaceuticals with scalable production from pre-clinical to full commercial, there are opportunities to partner on new nuclear medicine diagnostics and therapies, especially for expanding US market coverage.

Small to Mid Market With 51-200 employees and revenue in the 1–10 million range, IBAMNA presents as a fit for mid-market sales motions, including bundled services, contract manufacturing, and distribution partnerships to scale capacity and reach.

Strategic Partners Parent organization Illinois Health and Science and affiliation with Zevacor Molecular suggest alignment on patient care outcomes; there may be co-sell opportunities with hospitals, clinics, and research centers within the IHS network.

Technology Enablement Current tech stack and online presence indicate readiness for digital enablement in sales processes; potential for customer portal, regulatory documentation support, and data-driven marketing to streamline radiopharmaceutical sourcing and service requests.